ReviewEndocrine reviews2013
The osteocyte: an endocrine cell ... and more.
Review in Endocrine reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 538 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
538 citing papers in PubMed, 1 synthesis or guideline pooled it, 992 citations in OpenAlex.
- Effects of exercise on bone mineral density in middle-aged and older men: A comprehensive meta-analysis.Archives of osteoporosis · 2023Pooled it
- General View of Arachidonic Acid (AA) Metabolism.Reviews of physiology, biochemistry and pharmacology · 2027Review
- Non-coding RNAs regulating autophagy in Osteoporosis: mechanistic insights and therapeutic potential.Molecular biology reports · 2026Review
- Dissecting Hypoxia Inducible Factor-Driven High Bone Mass Phenotype in Mice Lacking Osteocytic Von Hippel-Lindau.JBMR plus · 2026Article
- Oxygen-dependent osteocyte transcriptomic adaptations occur without modulation of endothelial gene expression via osteocyte paracrine signaling.JBMR plus · 2026Article
- Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.Biogerontology · 2026Review
- Fibroblast growth factor receptor signaling in maturing osteoblasts controls cell-matrix interactions critical for osteocyte survival.Bone research · 2026Article
- Transcriptome-wide splicing analysis reveals HuR-regulated post-transcriptional programs in osteocytes.iScience · 2026Article
- Visualizing the Osteocyte Lacuno-Canalicular System via a Rapid 10-Minute Silver Nitrate Staining Method.Bio-protocol · 2026Article
- Osteocyte-vascular Interactions in Bone Physiology and Pathology.Current osteoporosis reports · 2026Review
- Review
- Osteocyte parvalbumin mediates mechanotransduction to attenuate osteoarthritis.Nature communications · 2026Article
- Unexpected periosteal bone apposition including newly embedded osteocytes occurs around a mouse calvaria critical defect, independently of the presence of biomaterials.Scientific reports · 2026Article
- Tunnelling Nanotube-Mediated Lysosome Sharing Promotes Osteocyte Survival via Transcellular Autophagy.Cell proliferation · 2026Article
- Sex specific effects of irisin on the skeleton.Bone research · 2026Review
- Microengineered bone models: advances and applications of bone-on-a-chip technology.Journal of biological engineering · 2026Review
- Genome-wide CRISPR interference screen identifies Clip2 as a novel regulator of osteocyte maturation and morphology.The Journal of biological chemistry · 2026Article
- Establishment of artificial intelligence-driven fluorescence morphometry reveals involvement of osteocyte perilacunar remodeling specifically in mandibular bone of ovariectomized rats.Microscopy (Oxford, England) · 2026Article
- Therapeutic strategy for exosome-based bone regeneration to osteoporosis: Challenges and potential solutions.Journal of advanced research · 2026Review
- Fibrin, from blood to bone: a review.Bone reports · 2026Review
478 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Few investigators think of bone as an endocrine gland, even after the discovery that osteocytes produce circulating fibroblast growth factor 23 that targets the kidney and potentially other organs. In fact, until the last few years, osteocytes were perceived by many as passive, metabolically inactive cells. However, exciting recent discoveries have shown that osteocytes encased within mineralized bone matrix are actually multifunctional cells with many key regulatory roles in bone and mineral homeostasis. In addition to serving as endocrine cells and regulators of phosphate homeostasis, these cells control bone remodeling through regulation of both osteoclasts and osteoblasts, are mechanosensory cells that coordinate adaptive responses of the skeleton to mechanical loading, and also serve as a manager of the bone's reservoir of calcium. Osteocytes must survive for decades within the bone matrix, making them one of the longest lived cells in the body. Viability and survival are therefore extremely important to ensure optimal function of the osteocyte network. As we continue to search for new therapeutics, in addition to the osteoclast and the osteoblast, the osteocyte should be considered in new strategies to prevent and treat bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.